T. Rowe Price Associates
LXEO icon

T. Rowe Price Associates’s Lexeo Therapeutics LXEO Stock Holding History

T. Rowe Price Associates’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$248K Buy
43,132
+9,260
+27% +$65.6K ﹤0.01% 2762
2025
Q4 		$337K Buy
33,872
+21,907
+183% +$200K ﹤0.01% 2590
2025
Q3 		$80K Buy
11,965
+1,540
+15% +$7.45K ﹤0.01% 2961
2025
Q2 		$42K Hold
10,425
– – ﹤0.01% 3017
2025
Q1 		$37K Hold
10,425
– – ﹤0.01% 2960
2024
Q4 		$69K Buy
+10,425
New +$82.1K ﹤0.01% 2891

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.71B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return